Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/14156
ชื่อเรื่อง: Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia
ผู้แต่ง: Hutspardol S.
Sirachainan N.
Anurathapan U.
Pakakasama S.
Songdej D.
Chuansumrit A.
Sirireung S.
Panthangkool W.
Hongeng S.
Keywords: aciclovir
amphotericin B
ciprofloxacin
corticosteroid
cyclophosphamide
cyclosporin A
fludarabine
granulocyte colony stimulating factor
itraconazole
mesna
metenolone enantate
methotrexate
mycophenolic acid 2 morpholinoethyl ester
penicillin derivative
tacrolimus
thymocyte antibody
allogeneic hematopoietic stem cell transplantation
aplastic anemia
article
blood transfusion
bone marrow transplantation
candidiasis
child
chimera
clinical article
continuous infusion
donor
engraftment
event free survival
female
fluorescence in situ hybridization
follow up
graft rejection
graft versus host reaction
human
male
neutrophil count
overall survival
peripheral blood stem cell
remission
school child
thrombocyte count
thrombocyte transfusion
Adolescent
Anemia, Aplastic
Child
Child, Preschool
Feasibility Studies
Female
Graft vs Host Disease
Host vs Graft Reaction
Humans
Immunosuppressive Agents
Infant
Male
Risk Factors
Stem Cell Transplantation
Survival Analysis
Transplantation, Homologous
วันที่เผยแพร่: 2013
บทคัดย่อ: Objective: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment for severe aplastic anemia (SAA). This is a single institutional review to study the feasibility of using allo-SCT for Thai children with SAA. Material and Method: Nine children with SAA (7 matched-sibling donor-SCT, 1 matched-unrelated donor-SCT and 1 haploidentical- SCT) underwent allo-SCT between October 2002 and September 2010. Cyclophosphamide and anti-thymocyte globulin (CY/ATG) were used as conditioning regimen for 4 patients with matched-sibling donor-SCT. CY/ATG and fludarabine were used for 3 patients with matched-sibling donor-SCT and one patient with haplo-identical SCT. One matched-unrelated donor-SCT received CY/ATG and total body irradiation. Results: Eight of 9 patients (89%) achieved neutrophil engraftment within 13.5 days (range 6.0-22.0). One matched-sibling donor-SCT recipient who failed to achieve engraftment died from acute renal failure and gram-negative sepsis on day 21 post allo-SCT. One matched-sibling donor-SCT case developed late graft failure on day 72 and died from invasive fungal infection. For graft versus host disease (GVHD), a haplo-identical-SCT patient died from steroid refractory grade IV acute GVHD. At last follow-up, six patients (67%) alive at a median follow-up time of 76.4 months (range 2.3-88.8). Overall survival (OS) and event-free survival (EFS) at 5 year was 63% and 65%, respectively. Conclusion: Allo-SCT is a feasible curative treatment for children with SAA in Thailand. Graft failure and severe GVHD in alternative donors SCT are responsible for major causes of death. OS and EFS probabilities are stable after the first year post transplant.
URI: https://ir.swu.ac.th/jspui/handle/123456789/14156
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876862072&partnerID=40&md5=d1108e6478bac4ed5fddeec783123f98
ISSN: 1252208
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.